Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of IPI-145 on the pharmacokinetics of midazolam, a cytochrome P450 3A
(CYP3A) substrate; to assess the safety and tolerability of IPI-145 when administered with
midazolam in healthy subjects.